Heterocyclic thioamide derivatives

Details Heterocyclic thioamide derivatives Heterocyclic thioamide derivatives

2001-05-23

2002-07-23

Rotman, Alan L. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S256000, C544S242000, C544S295000, C544S335000, C546S329000, C546S268100, C546S336000, C546S337000

Reexamination Certificate

active

06423728

ABSTRACT:

CROSS REFERENCE TO RELATED APPLICATIONS
This application is related to:
Chen, et al. U.S. Ser. No. 09/138,353 filed Aug. 21, 1998,
Title: N-ALKANOYLPHENYLALANINE DERIVATIVES; and
Chen, et al. U.S. Ser. No. 09/137,798 filed Aug. 21, 1998,
Title: N-AROYLPHENYLALANINE DERIVATIVES.
BACKGROUND OF THE INVENTION
Vascular cell adhesion molecule-1 (VCAM-1), a member of the immunoglobulin (Ig) supergene family, is expressed on activated, but not resting, endothelium. The integrin VLA-4 (a
4
b
1
), which is expressed on many cell types including circulating lymphocytes, eosinophils, basophils, and monocytes, but not neutrophils, is the principal receptor for VCAM-1. Antibodies to VCAM-1 or VLA-4 can block the adhesion of these mononuclear leukocytes, as well as melanoma cells, to activated endothelium in vitro. Antibodies to either protein have been effective at inhibiting leukocyte infiltration and preventing tissue damage in several animal models of inflammation. Anti-VLA-4 monoclonal antibodies have been shown to block T-cell emigration in adjuvant-induced arthritis, prevent eosinophil accumulation and bronchoconstriction in models of asthma, and reduce paralysis and inhibit monocyte and lymphocyte infiltration in experimental autoimmune encephalitis (EAE). Anti-VCAM-1 monoclonal antibodies have been shown to prolong the survival time of cardiac allografts. Recent studies have demonstrated that anti-VLA-4 mAbs can prevent insulitis and diabetes in non-obese diabetic mice, and significantly attenuate inflammation in the cotton-top tamarin model of colitis.
Thus, compounds which inhibit the interaction between &agr;
4
-containing integrins and VCAM-1 will be useful as therapeutic agents for the treatment of inflammation resulting from chronic inflammatory diseases such as rheumatoid arthritis, multiple sclerosis (MS), asthma, and inflammatory bowel disease (IBD).
SUMMARY OF THE INVENTION
It has been discovered that compounds of the formula:
and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronicinflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (IBD).


REFERENCES:
patent: 3023235 (1962-02-01), Leonard
patent: 3527793 (1970-09-01), Holdrege
patent: 5463116 (1995-10-01), Sumikawa et al.
patent: 5804595 (1998-09-01), Portoghese et al.
patent: 6229011 (2001-05-01), Chen et al.
patent: 2004127 (1990-06-01), None
patent: 195 48 709 (1997-07-01), None
patent: 196 54 483 (1998-01-01), None
patent: 0 207 681 (1987-01-01), None
patent: WO 95/35296 (1995-12-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 97/36859 (1997-10-01), None
patent: WO 97/36862 (1997-10-01), None
patent: WO 98/53814 (1998-12-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/43642 (1999-09-01), None
patent: WO 99/48879 (1999-09-01), None
patent: WO 99/61465 (1999-12-01), None
Advanced Organic Chemistry, 2ndEd, McGraw Hill (1977) pp. 246-259.
Scheibey, S. et al, Bull. Soc. Chim. Belg. (1978) vol. 87, pp. 229-238.
CAVA, M.P. et al, Tetrahedron (1985) vol. 41, pp. 5061-5087.
Meyers, A.I., et al, J. Org. Chem. (1978) vol. 43, pp. 1372-1379.
Von Arx, E. et al, J. Chromatography, (1976) vol. 120, pp. 224-228.
English Abstract for BI—DE 195 48 709.
English Abstract for Document B2 DE 196 54 483.
Denko, S., Patent Abstracts of Japan, vol.. 013, No. 029 (C-562), (1989)—JP 63233963A.
Abstract corresponding to JP 63233963.
Patani, et al, Chemical Reviews, (1996) vol. 96, pp. 3147-3176.

Affiliated with

Also associated with

Rating

Heterocyclic thioamide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic thioamide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic thioamide derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2867032